MX2011011776A - Nuevos profarmacos de triptolite. - Google Patents

Nuevos profarmacos de triptolite.

Info

Publication number
MX2011011776A
MX2011011776A MX2011011776A MX2011011776A MX2011011776A MX 2011011776 A MX2011011776 A MX 2011011776A MX 2011011776 A MX2011011776 A MX 2011011776A MX 2011011776 A MX2011011776 A MX 2011011776A MX 2011011776 A MX2011011776 A MX 2011011776A
Authority
MX
Mexico
Prior art keywords
formula
compounds
triptolide prodrugs
triptolide
prodrugs
Prior art date
Application number
MX2011011776A
Other languages
English (en)
Spanish (es)
Inventor
Ingrid Gunda Georg
Satish Prakash Patil
Ashok K Saluja
Rohit Chugh
Selwyn M Vickers
Original Assignee
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota filed Critical Univ Minnesota
Publication of MX2011011776A publication Critical patent/MX2011011776A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/665Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572Five-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
MX2011011776A 2009-05-07 2010-05-07 Nuevos profarmacos de triptolite. MX2011011776A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17624909P 2009-05-07 2009-05-07
PCT/US2010/034117 WO2010129918A1 (en) 2009-05-07 2010-05-07 Triptolide prodrugs

Publications (1)

Publication Number Publication Date
MX2011011776A true MX2011011776A (es) 2012-08-03

Family

ID=42244313

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011776A MX2011011776A (es) 2009-05-07 2010-05-07 Nuevos profarmacos de triptolite.

Country Status (17)

Country Link
US (1) US8507552B2 (enExample)
EP (1) EP2427467B1 (enExample)
JP (3) JP6000122B2 (enExample)
KR (1) KR101821823B1 (enExample)
CN (1) CN102596977B (enExample)
AU (1) AU2010245669B2 (enExample)
BR (1) BRPI1014802B8 (enExample)
CA (2) CA2760953C (enExample)
DK (1) DK2427467T3 (enExample)
EA (1) EA021135B1 (enExample)
ES (1) ES2552163T3 (enExample)
MX (1) MX2011011776A (enExample)
MY (1) MY160392A (enExample)
PL (1) PL2427467T3 (enExample)
PT (1) PT2427467E (enExample)
SG (1) SG175885A1 (enExample)
WO (1) WO2010129918A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9150600B2 (en) 2009-05-07 2015-10-06 Regents Of The University Of Minnesota Triptolide prodrugs
DK3510860T3 (da) 2012-08-23 2021-10-18 Senestech Inc Nedsættelse af pattedyrs reproduktive kapacitet
WO2014047783A1 (zh) * 2012-09-25 2014-04-03 鼎泓国际投资(香港)有限公司 含有雷公藤甲素及雷公藤甲素类衍生物和Bcl-2抑制剂的药物组合物及其应用
WO2014167581A2 (en) * 2013-04-01 2014-10-16 Laurus Labs Private Limited An improved process for the preparation of triptolide prodrugs
JP6931228B2 (ja) * 2015-09-11 2021-09-01 ワイズ・エー・シー株式会社 抗cd26抗体と他の抗癌剤とを組み合わせた癌治療用組成物
CN109942665B (zh) * 2018-04-02 2021-04-06 欣凯医药化工中间体(上海)有限公司 雷公藤内酯醇衍生物及其制备方法和应用
CN110551171B (zh) * 2018-05-31 2021-07-27 欣凯医药化工中间体(上海)有限公司 一种雷公藤内酯醇衍生物的制备方法
CN113056474A (zh) * 2018-09-13 2021-06-29 米尼阿姆里塔治疗学有限责任公司 用于治疗纤维化、nash和nafld的方法中的雷公藤内酯及其前药
WO2021221179A1 (ja) * 2020-04-28 2021-11-04 国立大学法人高知大学 ヒト膵癌オルガノイドを用いたマウスモデルの樹立
US20230303618A1 (en) 2020-08-21 2023-09-28 Reyoung Corporation Triptolide conjugates and uses thereof
CN115227829B (zh) * 2022-02-22 2023-10-13 成都中医药大学 酸敏感性适配体雷公藤甲素偶联物及应用
KR102821060B1 (ko) 2023-03-09 2025-06-16 미네암리타 테라퓨틱스, 엘엘씨 위암의 치료를 위한 약물 조합
KR20250154513A (ko) 2023-03-09 2025-10-28 미네암리타 테라퓨틱스, 엘엘씨 췌장암 치료용 약물 조합
WO2024187139A1 (en) 2023-03-09 2024-09-12 Minneamrita Therapeutics Llc Drug combination for treatment of gastric cancer

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843452A (en) 1992-11-09 1998-12-01 Pharmagenesis, Inc. Immunotherapy composition and method
US5759550A (en) 1993-05-06 1998-06-02 Pharmagenesis, Inc. Method for suppressing xenograft rejection
US5609991A (en) 1995-02-10 1997-03-11 Morton International, Inc. Photoimageable composition having improved alkaline process resistance and tack-free surface for contact imaging
US5663335A (en) 1996-03-01 1997-09-02 Pharmagenesis, Inc. Immunosuppressive compounds and methods
US5962516A (en) 1997-02-28 1999-10-05 Pharmagenesis, Inc. Immunosuppressive compounds and methods
US6204257B1 (en) * 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
US6548537B1 (en) 1998-09-02 2003-04-15 Pharmagenesis, Inc. Triptolide prodrugs having high aqueous solubility
DE69909633T2 (de) * 1998-09-02 2004-05-13 Pharmagenesis, Inc., Palo Alto Gut wasserlösliche triptolid-prodrugs
AU3365800A (en) 1999-02-16 2000-09-04 Board Of Trustees Of The Leland Stanford Junior University Combined therapy of diterpenoid triepoxides and trail for synergistic killing oftumor cells
AU5368699A (en) 1999-04-16 2000-11-02 Chengdu Diao Pharmaceutical Group Company Limited Derivatives of triptolide, and preparation and uses thereof
US6294546B1 (en) 1999-08-30 2001-09-25 The Broad Of Trustees Of The Leland Stanford Junior University Uses of diterpenoid triepoxides as an anti-proliferative agent
US6620843B2 (en) * 2001-01-19 2003-09-16 Pharmagenesis Anticancer treatment using triptolide prodrugs
US6569893B2 (en) * 2001-03-15 2003-05-27 Pharmagenesis, Inc. Amino acid derivatives of triptolide compounds as immune modulators and anticancer agents
UA77033C2 (uk) * 2001-12-21 2006-10-16 Mgi Gp Inc Спосіб отримання водорозчинних фосфонооксиметильних похідних спирту та фенолу
US7847109B2 (en) 2002-05-31 2010-12-07 Pharmagenesis, Inc. Triptolide derivatives for modulation of apoptosis and immunosuppression
CN100398544C (zh) * 2002-09-18 2008-07-02 成都达远药物有限公司 高免疫抑制活性的水溶性雷公藤内酯醇衍生物及其应用
AU2003297211A1 (en) 2002-12-17 2004-07-22 Pharmagenesis, Inc. Triptolide derivatives as immunomodulator and anticancer agents
CN1223595C (zh) 2002-12-27 2005-10-19 中国科学院上海药物研究所 雷公藤内酯醇衍生物及其应用
US6943259B2 (en) 2003-02-25 2005-09-13 Pharmagenesis, Inc. Halogenated triptolide derivatives as immunomodulators and anticancer agents
WO2005020887A2 (en) 2003-06-27 2005-03-10 Pharmagenesis, Inc. Method for treatment of severe acute respiratory syndrome
US7820834B2 (en) 2003-12-24 2010-10-26 Pharmagenesis, Inc. Triptolide 5,6-derivatives as immunomodulators and anticancer agents
JP5252765B2 (ja) 2003-12-26 2013-07-31 学校法人東京薬科大学 皮脂産生抑制剤及び皮脂腺発達抑制剤、並びに、皮膚外用剤
ATE554758T1 (de) 2004-03-02 2012-05-15 Pharmagenesis Inc Triptolid-lacton-ring-derivate als immunmodulatoren und mittel gegen krebs
US20070244080A1 (en) 2004-06-25 2007-10-18 Pharmagenesis, Inc. Method for Treatment of Inflammatory Disorders Using Triptolide Compounds
WO2007025031A2 (en) * 2005-08-24 2007-03-01 Cephalon, Inc. Prodrugs of indanone and tetralone compounds
CN101049300A (zh) 2006-04-04 2007-10-10 中国科学院上海药物研究所 包含雷公藤内酯醇衍生物的药物组合物、其剂型和应用
CA2658793A1 (en) * 2006-07-25 2008-02-07 Daniel Dumas Quinoline derivatives
EP2133355A4 (en) * 2007-03-06 2011-12-28 Eisai R&D Man Co Ltd COMPOSITION WITH A CHLOROMETHYPHOSPHATE DERIVATIVE WITH INCREASED STABILITY AND METHOD FOR THE PRODUCTION THEREOF
FI20070574A0 (fi) * 2007-07-30 2007-07-30 Kuopion Yliopisto Vesiliukoinen propofolin etylideenifosfaatti-aihiolääke
WO2009023201A1 (en) 2007-08-16 2009-02-19 Myelorx Llc Rigid derivatives of triptolide as anticancer, immune suppressant, anti-fibrosis, and cns protectant agents

Also Published As

Publication number Publication date
CA2760953C (en) 2017-05-30
EP2427467A1 (en) 2012-03-14
EP2427467B1 (en) 2015-08-05
PL2427467T3 (pl) 2016-04-29
EA201190293A1 (ru) 2012-11-30
CA2760953A1 (en) 2010-11-11
MY160392A (en) 2017-03-15
WO2010129918A1 (en) 2010-11-11
ES2552163T3 (es) 2015-11-26
WO2010129918A8 (en) 2011-01-20
JP2014185181A (ja) 2014-10-02
JP6000122B2 (ja) 2016-09-28
AU2010245669A1 (en) 2011-12-01
KR20120015339A (ko) 2012-02-21
JP2016065099A (ja) 2016-04-28
US8507552B2 (en) 2013-08-13
BRPI1014802B1 (pt) 2020-09-24
AU2010245669B2 (en) 2015-11-26
KR101821823B1 (ko) 2018-01-24
CN102596977A (zh) 2012-07-18
HK1168107A1 (en) 2012-12-21
DK2427467T3 (en) 2015-11-09
CA2964631A1 (en) 2010-11-11
CN102596977B (zh) 2016-06-29
SG175885A1 (en) 2011-12-29
JP2012526148A (ja) 2012-10-25
BRPI1014802B8 (pt) 2021-05-25
PT2427467E (pt) 2015-11-19
BRPI1014802A2 (pt) 2016-04-05
US20120238529A1 (en) 2012-09-20
EA021135B1 (ru) 2015-04-30

Similar Documents

Publication Publication Date Title
MX2011011776A (es) Nuevos profarmacos de triptolite.
MY148253A (en) Azaadamantane derivatives and methods of use
MX2010009752A (es) Compuestos de oxadiazoantraceno para el tratamiento de diabetes.
EA201170872A1 (ru) Ингибиторы протеинкиназы
MX2014001595A (es) Compuestos de imidazol, composiciones y metodos de uso.
TN2012000152A1 (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
TN2012000248A1 (en) Novel spiropiperidine compounds
MY187718A (en) Pharmaceutical formulations
MX2011011661A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
MX2010009646A (es) Agentes terapeuticos antivirales.
TN2011000291A1 (en) Purine compounds
MY172924A (en) Neprilysin inhibitors
MY153958A (en) Lxr modulators
MX2009008660A (es) Metodo para la preparacion de derivados de trifenilbuteno terapeuticamente valiosos.
WO2013109972A3 (en) Therapeutic compounds
IN2012DN01292A (enExample)
PH12014502492A1 (en) Pyrazole compounds as sglt1 inhibitors
IN2012DN05081A (enExample)
AU2011380449A8 (en) Iodination process for the preparation of 3,5-disubstituted-2,4,6-triiodo aromatic amines compounds
IN2012DN02000A (enExample)
PH12013500051A1 (en) Crystalline form of a 3-phenoxymethylpyrrolidine compound
MX2010003056A (es) Polimorfos de valomaciclovir.
GB2511240A (en) Nitrofurfuryl substituted phenyl linked piperidino-oxadiazoline conjugates as anti-tubercular agents and process for the preparation thereof
MX2013002656A (es) Nuevo proceso.
IN2012DN00346A (enExample)

Legal Events

Date Code Title Description
FG Grant or registration